Eli Lilly and Company (Acquirer)
Biotech Investor · 3 portfolio companies
Portfolio
3
Combined Value
$1.0B
Focus Areas
6
Top Stage
Phase 2
Investment Focus
Portfolio Companies
| Company | Valuation |
|---|---|
| Ventyx Biosciences | $1.0B |
| Prevail Therapeutics | — |
| Protomer Technologies | — |